vs
Side-by-side financial comparison of FLAGSTAR BANK, NATIONAL ASSOCIATION (FLG) and Bio-Techne (TECH). Click either name above to swap in a different company.
FLAGSTAR BANK, NATIONAL ASSOCIATION is the larger business by last-quarter revenue ($498.0M vs $295.9M, roughly 1.7× Bio-Techne). Bio-Techne runs the higher net margin — 12.8% vs 4.2%, a 8.6% gap on every dollar of revenue. On growth, FLAGSTAR BANK, NATIONAL ASSOCIATION posted the faster year-over-year revenue change (1.6% vs -6.4%). Over the past eight quarters, Bio-Techne's revenue compounded faster (4.2% CAGR vs -10.7%).
Flagstar Bank was an American commercial bank headquartered in Troy, Michigan. The bank was founded in 1987 and operated as a consumer and commercial bank, mortgage lender, and offered financial services. Flagstar Bancorp, Inc. was acquired by New York Community Bancorp, Inc. on December 1, 2022. New York Community Bancorp subsequently rebranded all of its branches under the Flagstar name and changed its name to Flagstar Financial in 2024. In a corporate restructuring in 2025 Flagstar Financi...
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
FLG vs TECH — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $498.0M | $295.9M |
| Net Profit | $21.0M | $38.0M |
| Gross Margin | — | 64.6% |
| Operating Margin | 11.4% | 18.4% |
| Net Margin | 4.2% | 12.8% |
| Revenue YoY | 1.6% | -6.4% |
| Net Profit YoY | -38.1% | 68.3% |
| EPS (diluted) | $0.03 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $498.0M | — | ||
| Q4 25 | $2.1B | $295.9M | ||
| Q3 25 | $425.0M | — | ||
| Q2 25 | $419.0M | $317.0M | ||
| Q1 25 | — | $316.2M | ||
| Q4 24 | $461.0M | $297.0M | ||
| Q3 24 | $510.0M | $289.5M | ||
| Q2 24 | $557.0M | $306.1M |
| Q1 26 | $21.0M | — | ||
| Q4 25 | $29.0M | $38.0M | ||
| Q3 25 | $-36.0M | — | ||
| Q2 25 | $-70.0M | $-17.7M | ||
| Q1 25 | — | $22.6M | ||
| Q4 24 | $-188.0M | $34.9M | ||
| Q3 24 | $-280.0M | $33.6M | ||
| Q2 24 | $-323.0M | $40.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% |
| Q1 26 | 11.4% | — | ||
| Q4 25 | — | 18.4% | ||
| Q3 25 | -9.6% | — | ||
| Q2 25 | -19.3% | -7.5% | ||
| Q1 25 | — | 12.2% | ||
| Q4 24 | -51.6% | 16.0% | ||
| Q3 24 | -65.7% | 13.8% | ||
| Q2 24 | -76.1% | 15.0% |
| Q1 26 | 4.2% | — | ||
| Q4 25 | 1.4% | 12.8% | ||
| Q3 25 | -8.5% | — | ||
| Q2 25 | -16.7% | -5.6% | ||
| Q1 25 | — | 7.1% | ||
| Q4 24 | -40.8% | 11.7% | ||
| Q3 24 | -54.9% | 11.6% | ||
| Q2 24 | -58.0% | 13.3% |
| Q1 26 | $0.03 | — | ||
| Q4 25 | $0.05 | $0.24 | ||
| Q3 25 | $-0.11 | — | ||
| Q2 25 | $-0.19 | $-0.11 | ||
| Q1 25 | — | $0.14 | ||
| Q4 24 | $-1.11 | $0.22 | ||
| Q3 24 | $-0.79 | $0.21 | ||
| Q2 24 | $-1.14 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $8.1B | $2.0B |
| Total Assets | $87.1B | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $172.9M | ||
| Q3 25 | $23.6B | — | ||
| Q2 25 | $22.9B | $162.2M | ||
| Q1 25 | — | $140.7M | ||
| Q4 24 | $25.8B | $177.5M | ||
| Q3 24 | $33.6B | $187.5M | ||
| Q2 24 | $29.5B | $152.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | $260.0M | ||
| Q3 25 | $13.2B | — | ||
| Q2 25 | $13.2B | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | $14.4B | $300.0M | ||
| Q3 24 | $20.3B | $300.0M | ||
| Q2 24 | $28.9B | $319.0M |
| Q1 26 | $8.1B | — | ||
| Q4 25 | $8.1M | $2.0B | ||
| Q3 25 | $8.1B | — | ||
| Q2 25 | $8.1B | $1.9B | ||
| Q1 25 | — | $2.0B | ||
| Q4 24 | $8.2B | $2.1B | ||
| Q3 24 | $8.6B | $2.1B | ||
| Q2 24 | $8.4B | $2.1B |
| Q1 26 | $87.1B | — | ||
| Q4 25 | $87.5M | $2.5B | ||
| Q3 25 | $91.7B | — | ||
| Q2 25 | $92.2B | $2.6B | ||
| Q1 25 | — | $2.6B | ||
| Q4 24 | $100.2B | $2.7B | ||
| Q3 24 | $114.4B | $2.7B | ||
| Q2 24 | $119.1B | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | 1.63× | — | ||
| Q2 25 | 1.63× | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | 1.77× | 0.14× | ||
| Q3 24 | 2.37× | 0.14× | ||
| Q2 24 | 3.44× | 0.15× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FLG
Segment breakdown not available.
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
